Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.

Professor Yimin Zou and colleagues have published surprising results that reveal that RYK expression inhibits wound healing, ...

Squibb announced that the U.S. Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for adult ...

Cogent Biosciences, Inc.’s COGT share price has dipped by 11.10%, which has investors questioning if this is right time to ...

Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect ...

It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and ...

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors ...

Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...